Accepted Manuscript

Archives of Plastic Surgery

Safety and Effectiveness of Liposuction Modalities in Managing Lipedema: Systematic Review and Meta-Analysis

Hatan H Mortada, Sultan Alaqil, Imtinan Al Jabbar, Fatimah Alhubail, Nicolas A Pereira, Joon P Hong, Feras Alshomer.

Affiliations below.

DOI: 10.1055/a-2334-9260

Please cite this article as: Mortada H H, Alaqil S, Al Jabbar I et al. Safety and Effectiveness of Liposuction Modalities in Managing Lipedema: Systematic Review and Meta-Analysis. Archives of Plastic Surgery 2024. doi: 10.1055/a-2334-9260

Conflict of Interest: The authors declare that they have no conflict of interest.

Abstract:

Introduction

Lipedema is a chronic, incurable disorder characterized by painful fat accumulation in the extremities. While the application of liposuction in lipedema management has become increasingly popular, the safety and effectiveness of this approach remain contentious. Our systematic review and meta-analysis aimed to assess various liposuction modalities in lipedema management to verify their safety and efficacy.

Methods

In line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we performed a comprehensive literature review from inception until March 2023 using the following electronic databases: CENTRAL, MEDLI-NE, Google Scholar, and EMBASE.

Results

From the 562 initially identified articles, 20 met our inclusion/exclusion criteria for evaluation. Our review encompassed 14 prospective cohort studies, three retrospective studies, two case series, and one cross-sectional study. A meta-analysis of nine articles revealed a notable improvement in the quality of life, pain, pressure sensitivity, bruising, cosmetic impairment, heaviness, walking difficulty, and itching among lipedema patients who underwent liposuction. Although complications such as inflammation, thrombosis, seroma, hematoma, and lymphedema-related skin changes were reported, severe complications were rare. Crucially, no instances of shock, recurrence, or mortality were reported. Conclusion

In conclusion, liposuction is a safe and beneficial therapeutic intervention for managing lipedema symptoms and enhancing quality of life. However, the impact of liposuction on secondary lymphedema remains unreported in the literature. Further high-quality, large-scale trials are necessary to assess the safety and effectiveness of different liposuction modalities. These studies will contribute valuable insights to optimize liposuction as a therapeutic option for individuals with lipedema.

Corresponding Author:

MBBS, MSc, SB-plast Feras Alshomer, Asan Medical Center, Department of Plastic and Reconstructive Surgery, Songpa-gu, Korea (the Republic of), dr.fshomer@gmail.com


Affiliations:

Hatan H Mortada, King Saud University Medical City, Division of Plastic Surgery, Department of Surgery, Riyadh, Saudi Arabia Hatan H Mortada, King Saud University, Department of Plastic Surgery, Riyadh, Saudi Arabia Sultan Alaqil, King Saud University, College of Medicine, Riyadh, Saudi Arabia

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



[...] Feras Alshomer, Asan Medical Center, Department of Plastic and Reconstructive Surgery, Songpa-gu, Korea (the Republic of)





Safety and Effectiveness of Liposuction Modalities in Managing Lipedema: Systematic Review and Meta-Analysis

Hatan Mortada, MBBS

Division of Plastic Surgery, Department of Surgery, King Saud University Medical City, King Saud University and Department of Plastic Surgery & Burn Unit, King Saud Medical City, Riyadh, Saudi Arabia

Sultan **Alaqil**, MBBS College of Medicine, King Saud University, Riyadh, Saudi Arabia

Imtinan **Al Jabbar**, Medical Student College of Medicine, King Khalid University, Abha, Saudi Arabia

Fatimah **Alhubail**, Medical Student, College of Medicine, King Faisal University, Alahsa, Saudi Arabia

Nicolas Pereira, MD, MSc

Specialized Center in Lymphedema and Lipedema, Clínica Nea, Hospital del Trabajador, Región Metropolitana, Chile

Joon Pio Hong, MD

Department of Plastic and Reconstructive Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.

Feras Alshomer, MBBS, SB-PLAST

Division of Plastic Surgery, Department of Surgery, King Saud bin Abdulaziz University for Health and Sciences, Riyadh, Saudi Arabia.

Corresponding author:

Feras **Alshomer**, MBBS, SB-PLAST Division of Plastic Surgery, Department of Surgery, King Saud bin Abdulaziz University for Health and Sciences, Riyadh, Saudi Arabia. dr.fshomer@gmail.com

Conflict of interest:

The authors do not have any conflict of interest.

Acknowledgment:

We would like to express our deepest gratitude to all the authors and researchers whose significant contributions in the form of previously published papers and studies have made this work possible. The breadth and depth of the insights presented in their work have been instrumental in shaping our research. Their meticulous efforts and pioneering work in this field have provided a solid foundation upon which our study stands. Their contributions to the body of knowledge surrounding this topic are not only appreciated but crucial for the advancement of this field of study. It is our honor to build upon their work and continue the dialogue that they have so capably initiated.

Abstract Introduction

Lipedema is a chronic, incurable disorder characterized by painful fat accumulation in the extremities. While the application of liposuction in lipedema management has become increasingly popular, the safety and effectiveness of this approach remain contentious. Our systematic review and meta-analysis aimed to assess various liposuction modalities in lipedema management to verify their safety and efficacy.

Methods

In line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we performed a comprehensive literature review from inception until March 2023 using the following electronic databases: CENTRAL, MEDLINE, Google Scholar, and EMBASE.

Results

From the 562 initially identified articles, 20 met our inclusion/exclusion criteria for evaluation. Our review encompassed 14 prospective cohort studies, three retrospective studies, two case series, and one cross-sectional study. A meta-analysis of nine articles revealed a notable improvement in the quality of life, pain, pressure sensitivity, bruising, cosmetic impairment, heaviness, walking difficulty, and itching among lipedema patients who underwent liposuction. Although complications such as inflammation, thrombosis, seroma, hematoma, and lymphedema-related skin changes were reported, severe complications were rare. Crucially, no instances of shock, recurrence, or mortality were reported.

Conclusion

In conclusion, liposuction is a safe and beneficial therapeutic intervention for managing lipedema symptoms and enhancing quality of life. However, the impact of liposuction on

secondary lymphedema remains unreported in the literature. Further high-quality, large-scale trials are necessary to assess the safety and effectiveness of different liposuction modalities. These studies will contribute valuable insights to optimize liposuction as a therapeutic option for individuals with lipedema.

Level of evidence: I, risk/prognostic study

Keywords

Lipedema; Liposuction; Lipoedema; Liposculpture; Lipoplasty; Quality of life; Suctionassisted lipectomy

Introduction

Lipedema is a chronic, symmetric, and incurable disorder impacting adipose tissue [1,2]. It typically manifests as a disproportionate, painful accumulation of fat in the extremities [3]. Commonly, it presents as bilateral enlargement of the lower limbs, including the buttocks, thighs, knees, and legs, while upper limbs are less frequently involved, and hands and feet are always spared [4]. The exact pathophysiology driving this unusual fat deposition is not yet fully understood [5]; however, previous studies indicate potential roles for genetic and hormonal influences [6,7]. Lipedema primarily affects women, often related to their state of constant hormonal changes [8,9]. Often, patients with lipedema experience feelings of shame due to frequent misdiagnosis as obesity [10], which can erode their trust in the healthcare system [11]. Furthermore, distressing symptoms such as disfigurement and pain can significantly impair quality of life, psychological health, and self-confidence [12]. As of now, lipedema remains incurable, prompting the development of different modalities to manage its symptoms [13]. However, the efficacy of conservative management is hotly debated, with most patients reportedly unresponsive to such treatment [14,15]. Thus, liposuction and its various modalities have recently gained traction as a potential means to manage lipedema's

painful and disfiguring symptoms [9,15]. Nonetheless, the safety and effectiveness of liposuction modalities for lipedema management remain controversial, with limited evidence to support their use. As such, we structured this systematic review and meta-analysis to evaluate the safety and effectiveness of different liposuction modalities in managing lipedema. This study assesses the outcomes of liposuction interventions, such as tumescent liposuction, laser-assisted liposuction, ultrasound-assisted liposuction, and water-assisted liposuction, regarding their safety and efficacy in managing lipedema. The findings of this study could help guide clinical practice and inform the development of standardized protocols for liposuction interventions in lipedema management. Through this study, we aim to provide valuable insights into lipedema management and contribute to ongoing efforts to improve the quality of life for patients with this condition. A secondary objective of this research is to assess and compare the different techniques to discern the most effective approach for lipedema outcomes.

Methods & Materials

Search Strategy

This systematic review was designed following the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines [16]. A comprehensive literature search was conducted from database inception until March 2023, across CENTRAL, MEDLINE, Google Scholar, and EMBASE, without any timeframe restrictions. To ensure a comprehensive result, the search employed the following key terms: "lipedema OR lipoedema" AND "Liposuction OR lipoplasty OR liposculpture OR fat removal OR adipose suction OR suction-assisted lipectomy OR fat removal" AND "complications OR outcomes OR patient-reported outcomes OR techniques." The review has been registered with the International Prospective Register of Systematic Reviews (ID:CRD42023411664).

The Rayyan collaboration platform was used for the initial screening of articles by title and abstract. Inclusion criteria encompassed: (1) studies reporting on patients who underwent liposuction for lipedema; (2) case series and original articles; (3) studies involving adult patients aged 18 years and above; (4) studies reporting on outcomes relevant to the clinical questions; (5) studies written in English. Exclusion criteria included: (1) non-English language studies; (2) editorials, letters, commentaries, or reviews; (3) studies not employing liposuction for managing lipedema; (4) studies reporting on outcomes not relevant to the study objectives; (5) studies with a high risk of bias or improper methods.

Data Extraction

Data extraction was independently performed by two authors from the text, tables, and figures of the included studies using a pre-designed, standardized extraction form. To ensure the reliability and accuracy of the extracted data, a second author independently reviewed the data extraction process, cross-checking all extracted data points against the original source materials to identify any discrepancies or missing information. This encompassed crucial data such as study characteristics (author, year of publication, study design, country of origin, and sample size), participant characteristics (age, sex, body mass index, disease severity, and disease duration), liposuction techniques were systematically categorized by fluid instillation (dry, wet, tumescent) and suction technology (conventional, power-assisted, laser-assisted, ultrasound-assisted), specialized techniques were also noted, intervention characteristics (type of liposuction modality used, volume of aspirate, number of procedures, and duration of follow-up), and outcome measures. The latter included safety outcomes such as the incidence of adverse events, and effectiveness outcomes including pain, edema, mobility, quality of life, secondary lymphedema, necrosis, and recurrence. The type of statistical analysis used to evaluate study outcomes was also noted. When data was unclear or incomplete,

corresponding authors were contacted for clarification. If missing data couldn't be obtained, a thorough explanation was provided concerning the missing data and its potential impact on the reported results. Data management was handled by the first author, in consultation with the second author.

Bias Assessment

Two authors independently used the methodological index for nonrandomized studies (MINORS) to assess the risk of bias in retrospective and prospective nonrandomized studies [17]. For case series, the methodological quality and synthesis of case series and case report assessment tool was utilized [18]. Potential bias was evaluated through funnel plots using the Egger test.

Statistical analysis:

All analyses were conducted using RevMan (version 5.4.1; Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2020). We extracted the means and standard deviations of the scores for the questions evaluating improvements in quality of life from the included studies, both pre- and post-liposuction. In our study's quantitative analysis, we excluded studies that reported median and Interquartile Range (IQR) values, in certain analysis. This exclusion was due to the necessity of mean and Standard Deviation (SD) values for certain statistical calculations, including Standardized Mean Differences (SMD). A weighted mean difference with 95% confidence intervals (CIs) was pooled using a fixed-effects model. Forest plots were created to evaluate the results of pooling. P value less than 0.05 was considered significant; Heterogeneity between trials was assessed using the Higgin I2 test according to the Cochrane Handbook.

Quality Assessment and Level of Evidence:

The quality of the 20 included articles was assessed by the authors, with 18 being nonrandomized non-comparative studies evaluated using the MINORS tool [17]. The remaining 2 case series articles were assessed using the methodological quality and synthesis assessment tool [18]. Two independent reviewers analyzed the risk of bias. This tool contains eight questions divided into four main domains: selection, ascertainment, causality, and reporting. Additionally, the MINORS tool, featuring 8 items for non-comparative studies and scored on a scale of 0 (not reported), 1 (reported but inadequate), or 2 (reported and adequate), was used. The maximum score for non-comparative studies was 16.

Results

Literature Review:

Initially, 562 articles were sourced from various databases. After deduplication and screenings, 20 articles met the inclusion/exclusion criteria [19-38]. Figure 1 provides an overview of the PRISMA process for conducting this systematic review. Table 1 presents the list of articles that mention the use of liposuction modalities in managing lipedema. The analysis comprised of two case series, one cross-sectional study, 14 prospective cohort studies, and three retrospective studies. It is important to highlight that no randomized clinical trials were identified among the studies included in the analysis. Table 1 lists the articles included in our systematic review, detailing the different liposuction modalities and methods, year of publication, and country of origin.

Patient Profile and Basic Characteristics:

The total number of patients with lipedema was reported to be 1,785. The mean age of the study participants was 39.987 years. The age of the patients included in the studies ranged from 16 to 81 years old. Among the studies that provided information on gender, a total of 1133 participants were identified as females. Various comorbidities were identified in the included data extracted from the articles. Most commonly included hypothyroidism (75

cases), allergies (72 cases), depression (48 cases), migraine (47 cases), sleep disorders (45 cases), arterial hypertension (28 cases), and asthma and bowel disorders (27 cases) were also noted. It is important to consider potential overlaps, as individual patients may have had multiple conditions. The overall mean body mass index (BMI) of the included patients preintervention was 33.3 ± 5.4 . One study provided data on post-intervention BMI, which showed a mean of 26.1 ± 5.4, as it was 28.4±4.5 [14]. Additionally, another study reported a pre-intervention mean BMI of 35.3 and a post-intervention mean BMI of 33.9 [22]. Among the included studies, the most commonly reported onset trigger was puberty, documented in 65 cases. Pregnancy was identified as the trigger in 22 cases, while contraceptives and menopause were reported in 4 and 2 cases, respectively. Among the included patients, all 1034 cases exhibited lower extremity lipedema, with 504 cases reporting involvement in the outer legs and 504 cases in the inner legs. A subset of 65 patients (6.3%) also showed upper extremity involvement in the arms. In specific cases, the affected areas were identified as arms and legs, hips and thighs, or arms, thighs, hips, knees, and calves to ankle. For the lower extremities, the most commonly affected areas were the thighs, calves, and buttocks. The thighs were further categorized into complete thighs, frontal parts, lateral sides, backside, and inside of thighs. Other affected areas included the frontal calves, calves, upper arms, forearms, back, and abdomen. In terms of leg involvement, 111 patients had lipedema, with the upper legs predominantly affected in 108 patients (97.3%) and more significant involvement in the lower legs observed in only 2 patients (1.8%). Among the 65 patients with upper extremity involvement, the arms were affected. A positive family history of lipedema was reported in the included data. About 17.44% (316 out of 1812) of patients had a positive family history of lipedema, without specifying which family members were affected.

Patients and Clinical Characteristics:

In our analysis of the liposuction techniques across the included studies, a predominant preference for the tumescent method of fluid instillation was observed. Of the 20 studies examined, 17 (81%) used the tumescent technique. Regarding the technology used for suction, the most commonly mentioned method was power-assisted liposuction, used in 35% of the cases (7 out of 20 articles). Water-assisted liposuction was employed either solely or in combination in 6 studies, accounting for 29%. Table 2 provides a summary of the liposuction techniques used in each study. In our review, 14 articles provided detailed information on the stages of lipedema in their patient cohorts. However, it is noteworthy that six articles did not specify the lipedema stages. The stage and grade distribution of lipedema among the included patients were as follows: 64 cases were classified as Stage I, 503 cases as Stage II, and 467 cases as Stage III, based on the staging system mentioned by Langendoen et al. and Katzer et al. [3,5]. Notably, there were no documented cases classified as Stage IV. The analysis of the data revealed that the overall mean number of treatment sessions was approximately 2.88±1.30, ranging from 1 to 5 sessions per patient. The overall mean volume of aspirate removed per session was approximately 4429.16 mL. However, it is important to note that the included studies did not consistently report the infiltrated volume, which is crucial for interpreting the volume of lipoaspirate. The duration of each liposuction session varied, ranging from 1 to 2.5 hours. Among the 20 studies included, 11 of them reported the use of

Patient-Reported Outcomes, and Complications

compression garments postoperatively.

Among the patient satisfaction evaluation methods used in the studies, Visual Analogue Scale (VAS) was employed in 6 studies. One study utilized the Freiburg Life Quality Assessment for lymphatic diseases questionnaire, another study used the Hanse-Klinik approved questionnaire, and one study employed the Body Shape Questionnaire (BSQ)/Lower Extremity Functional Scale (LEFS). To overcome outcome measurement differences among

the studies, we used the standardized mean difference (SMD) as a summary statistic in our meta-analysis. This enabled us to compare the effects of the intervention on a consistent scale, despite variations in outcome measurement approaches. The meta-analysis consistently illustrated significant improvements post-liposuction in patients with lipedema in areas like quality of life (SMD 2.48, p-value <0.0001) (figure 2), pain (SMD 2.04, p-value <0.0001) (figure 3), pressure sensitivity (SMD 2.2, p <0.0001) (figure 4), bruising (SMD 1.61, p-value < 0.0001) (figure 5), cosmetic appearance (SMD 2.07, p-value < 0.0001) (figure 6), and heaviness (SMD 2.01, p-value <0.0001) (figure 7). Lastly, the improvement in difficulty in walking after liposuction was reported in only two studies, showing a significant effect with a p-value <0.00001, SMD = 1.34 (95% CI: 1.12-1.56), and I² = 86%, figure 8. We have compared pre- and post-liposuction data, revealing notable improvements in lipedema symptoms following the procedure. Pain levels decreased by 72.39%, sensitivity to pressure by 68.13%, bruising by 52.32%, cosmetic impairment by 57.36%, and the sensation of heaviness by 50.85%. Additionally, there was a significant reduction in difficulty walking, which decreased by 78.47%. Overall, the reported complications included inflammation in 25 cases and thrombosis in 1 case. Individual cases presented specific complications such as skin changes consistent with lymphedema, foot and ankle swelling, dermal fibrosis, dermal sclerosis, hyperkeratosis, and persistent pigment irregularities. Other reported complications included mild arm-vein phlebitis in two patients, an episode of postsurgical anemia requiring a blood transfusion in one patient, and microscopic pulmonary fat embolism in another patient. Some cases did not report any complications, while one case reported deep vein thrombosis. Among the patients included in the study, a total of 14 individuals developed seroma (0.82%), 10 experienced infections (0.59%), 12 had hematoma (0.71%), 2 encountered bleeding (0.12%), 2 had skin necrosis (0.12%), and 3 developed secondary

lymphedema (0.18%). The mean follow-up duration for the patients was 15.14 months, ranging from 1 month to 96 months (8 years) (table 3).

Quality Assessment and Bias Evaluation:

The included studies in this analysis had varying levels of evidence. Out of the total studies, 15 were classified as Level II evidence. The MINORS tool was employed to gauge the quality of the non-randomized studies included in this systematic review [1]. Total scores varied from 6 to 14, averaging 10. Items scoring the least included unbiased assessment of the study endpoint (a score of 0 in all studies), prospective calculation of the study size (a score of 0 in most studies), and a less than 5% loss to follow-up (a score of 0 in over half of the studies). Items with the highest scores were endpoints appropriate to the study's aim (a score of 2 in nearly all studies), clearly stated study aims (a score of 2 in most studies), and a follow-up period appropriate to the study's aim (a score of 2 in most studies) and synthesis assessment tool were used to evaluate the risk of bias in case studies [2]. Both included case series scored 10.62 in terms of quality (Table 4).

Discussion

Complex Decongestive Therapy (CDT) is typically the initial treatment choice for lipedema in many countries. The aim of this treatment is to stop the progression of the condition and alleviate swelling. However, many patients continue to experience an increase in subcutaneous fat and a worsening of symptoms [37]. The tumescent technique for liposuction, introduced in the late 1980s, improved safety and minimized damage to lymphatic vessels [35,41]. Consequently, liposuction started to be considered as a potential approach for treating lipedema and reducing fat tissue.

This systematic review evaluated the effectiveness and safety of liposuction in individuals diagnosed with lipedema. A total of 20 articles, encompassing 1,785 patients, were included in the review. Among these, 1,133 patients were identified as females, with no males reported

in the data extracted from the articles. The majority of these patients were classified as stage 2 (503 individuals), followed by stage 3 (467 individuals), and a smaller subgroup of stage 1 (64 individuals). The most frequently identified comorbidities were hypothyroidism and allergies, followed by depression, migraine, sleep disorders, arterial hypertension, asthma, and bowel disorders. Lipedema was predominantly observed in the outer and inner legs, and arms. Tumescent liposuction was the most commonly used technique, followed by Power-assisted liposuction and Water-assisted liposuction.

The meta-analysis of 9 articles showed a significant improvement in patients' overall wellbeing, indicating considerable positive outcomes. Liposuction was found to effectively alleviate a range of symptoms associated with lipedema, such as pain, sensitivity to pressure, bruising, cosmetic concerns, heaviness, and mobility difficulties. Additionally, the procedure provided relief from itchiness, a specific symptom experienced by patients. These findings are consistent with reviews conducted by MacDougall D [42] and Ghods, M [5], further supporting liposuction as an effective treatment for improving symptoms and overall quality of life in individuals with lipedema. Despite a few reported complications including inflammation, thrombosis, seroma, hematoma, and lymphedema-related skin changes, severe complications were rare. Notably, no instances of shock, recurrence, or death were reported in the analyzed cases, underscoring the overall safety of liposuction as an intervention. The average follow-up period for patients included in the studies was approximately 15

months, with a range from 1 month to 96 months (8 years), which adds to the credibility and applicability of the findings. These results strongly advocate for liposuction as a safe, effective treatment option for managing lipedema symptoms, leading to significant improvements in patients' overall well-being. To the best of our knowledge, this is the first systematic review and meta-analysis to evaluate the safety and efficacy of different liposuction modalities in managing lipedema. The study has several strengths, such as compliance with the PRISMA guidelines, strict inclusion and exclusion criteria, comprehensive literature review without specific time constraints, inclusion of studies with moderate to high levels of evidence, and providing ample data to support a meta-analysis. According to the MINORs' assessment tool, most studies scored a mean of 9.7 for potential bias. The methodological quality and synthesis assessment tool showed a quality score of 7, and a moderate risk of bias for the two included case series. However, the study does have limitations. Firstly, most of our results were based on prospective cohort studies, potentially leading to some publication bias. Secondly, some studies did not include all the necessary details in their reported data, which may have resulted in some deficits in comparison. Thirdly, 14 out of the 20 studies included in the review were from Germany, suggesting an underrepresentation of other areas of practice. Further research should prioritize the need for randomized control trials to assess the safety and effectiveness of different liposuction modalities. This should be accomplished through high-quality, large-scale, and multicenter studies. While there are multiple liposuction techniques that may yield similar outcomes, the lack of comparative studies hinders any definitive conclusion about the superiority of one method over another. Tumescent technique is often regarded as highly efficient with the lowest complication rates. However, the metaanalysis highlighted significant heterogeneity in the techniques utilized across studies, making direct comparisons between water-assisted, ultrasound-assisted, and power-assisted liposuction challenging. The variable reporting on the use of tumescence and its potential implications, especially in secondary lymphedema, further muddles the waters. There's a pressing need for standardized liposuction protocols and clarity on tumescence's role. Specific recommendations for standardization could include defining the composition of the tumescent solution, establishing guidelines for infiltration volume and rate, setting precise timing and duration for tumescence, and refining patient selection criteria. Additionally, outlining surgical techniques, postoperative care strategies, and outcome measurement protocols could significantly enhance the efficacy and safety of liposuction procedures. It's imperative that future research concentrates on these areas to discern the efficacy and safety of the various liposuction techniques. Our study's limitation includes the potential overlap of patient cohorts in longitudinal studies, such as those by Schmeller (2012), Baumgartner (2016, 2021), and Rapprich (2011, 2015). This overlap could lead to some patients being counted multiple times in our reported total of 1785. Such repeated inclusions may slightly overestimate the number of unique patients, a factor to consider when interpreting our findings on lipedema prevalence and treatment outcomes. Our study highlights the importance of preoperative imaging for assessing lymphatic dysfunction in liposuction patients. We recommend future research to explore the use of imaging techniques like lymphoscintigraphy or near-infrared fluorescence imaging in preoperative evaluations. Such investigations could reveal crucial insights into lymphatic involvement, influencing surgical strategies and improving patient outcomes in lipedema and related conditions. In addition, our analysis reveals a need for more research on postoperative care in liposuction, particularly regarding the use and impact of compression garments. The inconsistency in their usage across studies suggests a lack of standardized practice. Future studies should focus on the efficacy of compression garments and their role in patient recovery. This could inform standardized guidelines for post-liposuction care, optimizing patient outcomes and minimizing postoperative complications.

Conclusion

Liposuction, especially the tumescent technique, is effective in treating lipedema, enhancing outcomes across different modalities. However, the literature lacks data on liposuction's impact on secondary lymphedema. Future research should focus on comprehensive trials with diverse designs, including long-term follow-ups and cost-effectiveness studies, to evaluate the safety and effectiveness of liposuction in lipedema. Future work should also determine safe lipoaspirate volumes to minimize complications, furthering our understanding of liposuction's benefits for lipedema patients. Integral to this future research is the exploration of true lymph-preserving liposuction, guided by indocyanine green lymphangiography and the avoidance of lymphatics during the procedure, a promising approach that warrants further investigation.

Statements and Declarations

Funding

The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.

Competing Interests

The authors have no relevant financial or non-financial interests to disclose.

Ethics approval

This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted was waived due to the nature of the study.

References

1. Allen EU, Hines EA. Lipedema of the legs: a syndrome characterized by fat legs and orthostatic edema. Proc Staff Mayo Clin. 1940;15:184-187.

Womens Health. 2016;8:389-395. Published 2016 Aug 11. doi:10.2147/IJWH.S106227 5. Kruppa P, Georgiou I, Biermann N, Prantl L, Klein-Weigel P, Ghods M. Lipedema-Pathogenesis, Diagnosis, and Treatment Options. Dtsch Arztebl Int. 2020;117(22-2021 Oct 29. doi:10.3390/ijms222111720

doi:10.1111/j.1365-2133.2009.09413.x

- 23):396-403. doi:10.3238/arztebl.2020.0396 6. Katzer K, Hill JL, McIver KB, Foster MT. Lipedema and the Potential Role of Estrogen in Excessive Adipose Tissue Accumulation. Int J Mol Sci. 2021;22(21):11720. Published
- 7. Michelini S, Herbst KL, Precone V, et al. A Multi-Gene Panel to Identify Lipedema-Predisposing Genetic Variants by a Next-Generation Sequencing Strategy. J Pers Med. 2022;12(2):268. Published 2022 Feb 11. doi:10.3390/jpm12020268
- 8. Földi M, Földi E, Kubik S. Textbook of lymphology: for physicians and lymphedema therapists. Urban & Fisher. 2006:417-427.
- 9. Forner-Cordero I, Szolnoky G, Forner-Cordero A, Kemény L. Lipedema: an overview of its clinical manifestations, diagnosis and treatment of the disproportional fatty deposition syndrome - systematic review. Clin Obes. 2012;2(3-4):86-95. doi:10.1111/j.1758-8111.2012.00045.x
- 10. Caruana M. Lipedema: A Commonly Misdiagnosed Fat Disorder. Plast Surg Nurs. 2018;38(4):149-152. doi:10.1097/PSN.00000000000245

3. Langendoen SI, Habbema L, Nijsten TE, Neumann HA. Lipoedema: from clinical

4. Warren Peled A, Kappos EA. Lipedema: diagnostic and management challenges. Int J

presentation to therapy. A review of the literature. Br J Dermatol. 2009;161(5):980-986.

- 11. Christoffersen V, Tennfjord MK. Younger Women with Lipedema, Their Experiences with Healthcare Providers, and the Importance of Social Support and Belonging: A Qualitative Study. Int J Environ Res Public Health. 2023;20(3):1925. Published 2023 Jan 20. doi:10.3390/ijerph20031925
- 12. Romeijn JRM, de Rooij MJM, Janssen L, Martens H. Exploration of Patient Characteristics and Quality of Life in Patients with Lipoedema Using a Survey. Dermatol Ther (Heidelb). 2018;8(2):303-311. doi:10.1007/s13555-018-0241-6
- Herbst KL, Kahn LA, Iker E, et al. Standard of care for lipedema in the United States. *Phlebology*. 2021;36(10):779-796. doi:10.1177/02683555211015887
- 14. Aksoy H, Karadag AS, Wollina U. Cause and management of lipedema-associated pain. Dermatol Ther. 2021;34(1):e14364. doi:10.1111/dth.14364
- 15. Fetzer A. Specialist approaches to managing lipoedema. *Br J Community Nurs*.2016;Suppl:S30-S35. doi:10.12968/bjcn.2016.21.Sup4.S30
- 16. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. 2021;372:n71. Published 2021 Mar 29. doi:10.1136/bmj.n71
- 17. Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73(9):712-716. doi:10.1046/j.1445-2197.2003.02748.x
- Murad MH, Sultan S, Haffar S, Bazerbachi F. Methodological quality and synthesis of case series and case reports. BMJ Evid Based Med. 2018;23(2):60-63. doi:10.1136/bmjebm-2017-110853
- Cornely M, Gensior M. Complications and their management in the surgical treatment of Lipohyperplasia dolorosa. English version [published online ahead of print, 2022 Dec 22]. Komplikationen und deren Management bei der chirurgischen Behandlung der

Lipohyperplasia dolorosa [published online ahead of print, 2022 Dec 22]. *Dermatologie (Heidelb)*. 2022;10.1007/s00105-022-05075-5. doi:10.1007/s00105-022-05075-5

- 20. Kruppa P, Georgiou I, Schmidt J, Infanger M, Ghods M. A 10-Year Retrospective beforeand-after Study of Lipedema Surgery: Patient-Reported Lipedema-Associated Symptom Improvement after Multistage Liposuction. Plast Reconstr Surg. 2022;149(3):529e-541e. doi:10.1097/PRS.00000000008880
- 21. Wright TF, Herbst KL. A Case Series of Lymphatic Injuries After Suction Lipectomy in Women with Lipedema. Am J Case Rep. 2022;23:e935016. Published 2022 Jul 11. doi:10.12659/AJCR.935016
- 22. Baumgartner A, Hueppe M, Meier-Vollrath I, Schmeller W. Improvements in patients with lipedema 4, 8 and 12 years after liposuction. Phlebology. 2021;36(2):152-159. doi:10.1177/0268355520949775
- 23. Sandhofer M, Hofer V, Sandhofer M, Sonani M, Moosbauer W, Barsch M. High Volume Liposuction in Tumescence Anesthesia in Lipedema Patients: A Retrospective Analysis. J Drugs Dermatol. 2021;20(3):326-334. doi:10.36849/JDD.5828
- 24. Schlosshauer T, Heiss C, von Hollen AK, Spennato S, Rieger UM. Liposuction treatment improves disease-specific quality of life in lipoedema patients. *Int Wound J*. 2021;18(6):923-931. doi:10.1111/iwj.13608
- 25. van de Pas CB, Boonen RS, Stevens S, Willemsen S, Valkema R, Neumann M. Does tumescent liposuction damage the lymph vessels in lipoedema patients?. Phlebology. 2020;35(4):231-236. doi:10.1177/0268355519885217
- 26. Witte T, Dadras M, Heck FC, et al. Water-jet-assisted liposuction for the treatment of lipedema: Standardized treatment protocol and results of 63 patients. J Plast Reconstr Aesthet Surg. 2020;73(9):1637-1644. doi:10.1016/j.bjps.2020.03.002

- 27. Bauer AT, von Lukowicz D, Lossagk K, et al. New Insights on Lipedema: The Enigmatic Disease of the Peripheral Fat. Plast Reconstr Surg. 2019;144(6):1475-1484. doi:10.1097/PRS.00000000006280
- 28. Wollina U, Heinig B. Treatment of lipedema by low-volume micro-cannular liposuction in tumescent anesthesia: Results in 111 patients. *Dermatol Ther*. 2019;32(2):e12820. doi:10.1111/dth.12820
- 29. Dadras M, Mallinger PJ, Corterier CC, Theodosiadi S, Ghods M. Liposuction in the Treatment of Lipedema: A Longitudinal Study. *Arch Plast Surg.* 2017;44(4):324-331. doi:10.5999/aps.2017.44.4.324
- 30. Baumgartner A, Hueppe M, Schmeller W. Long-term benefit of liposuction in patients with lipoedema: a follow-up study after an average of 4 and 8 years. Br J Dermatol. 2016;174(5):1061-1067. doi:10.1111/bjd.14289
- 31. Rapprich, S., Baum, S., Kaak, I., Kottmann, T. and Podda, M., 2015. Treatment of lipoedema using liposuction. *Phlebologie*, *44*(03), pp.121-132.
- 32. Wollina U, Heinig B, Nowak A. Treatment of elderly patients with advanced lipedema: a combination of laser-assisted liposuction, medial thigh lift, and lower partial abdominoplasty. Clin Cosmet Investig Dermatol. 2014;7:35-42. Published 2014 Jan 23. doi:10.2147/CCID.S56655
- 33. Rapprich S, Dingler A, Podda M. Liposuction is an effective treatment for lipedemaresults of a study with 25 patients. J Dtsch Dermatol Ges. 2011;9(1):33-40. doi:10.1111/j.1610-0387.2010.07504.x
- 34. Wollina U, Goldman A, Heinig B. Microcannular tumescent liposuction in advanced lipedema and Dercum's disease. G Ital Dermatol Venereol. 2010;145(2):151-159.

- 35. Stutz JJ, Krahl D. Water jet-assisted liposuction for patients with lipoedema: histologic and immunohistologic analysis of the aspirates of 30 lipoedema patients. Aesthetic Plast Surg. 2009;33(2):153-162. doi:10.1007/s00266-008-9214-y
- 36. Schmeller W, Meier-Vollrath I. Tumescent liposuction: a new and successful therapy for lipedema. J Cutan Med Surg. 2006;10(1):7-10. doi:10.1007/7140.2006.00006
- 37. Schmeller W, Hueppe M, Meier-Vollrath I. Tumescent liposuction in lipoedema yields good long-term results. Br J Dermatol. 2012;166(1):161-168. doi:10.1111/j.1365-2133.2011.10566.x
- 38. Herbst KL, Hansen EA, Cobos Salinas LM, Wright TF, Larson EE, Schwartz JS. Survey Outcomes of Lipedema Reduction Surgery in the United States. Plast Reconstr Surg Glob Open. 2021;9(4):e3553. Published 2021 Apr 23. doi:10.1097/GOX.00000000003553
- 39. Fife CE, Maus EA, Carter MJ, . Lipedema: a frequently misdiag- nosed and misunderstood fatty deposition syndrome. Adv Skin Wound Care. 2010;23:81-94. doi:10.1097/01.ASW.0000363503.92360.91
- 40. Meier-Vollrath I, Schmeller W, . Lipödem--aktueller Stand, neue Perspektiven
 [Lipoedema--current status, new perspectives]. J Dtsch Dermatol Ges. 2004;2(3):181186. doi:10.1046/j.1439-0353.2004.04051.x
- 41. Hoffmann JN, Fertmann JP, Baumeister RG, Putz R, Frick A. Tumescent and dry liposuction of lower extremities: differences in lymph vessel injury. Plast Reconstr Surg. 2004;113(2):718-726. doi:10.1097/01.PRS.0000101506.84361.C9
- 42. Peprah K, MacDougall D. Liposuction for the Treatment of Lipedema: A Review of Clinical Effectiveness and Guidelines. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; June 7, 2019.

43. Housman TS, Lawrence N, Mellen BG, et al. The safety of liposuction: results of a national survey. Dermatol Surg. 2002;28(11):971-978. doi:10.1046/j.1524-4725.2002.02081.x

Table 1. Basic demographics of the included articles

Table 2. Comparison of Intervention and Control Groups in a Study AssessingLiposuction Modalities for Lipedema

Table 3: Overview of Liposuction Techniques in Included Studies.

Table 4: MINORS assessment tool for non-randomized non-comparative studies (N=18)

Table 4: The methodological quality and synthesis of case series and case reportsassessment tool (N=2)

Figure 1. PRISMA flowchart illustrating the study selection process. The diagram outlines the number of studies identified, screened, assessed for eligibility, and included in the systematic review and meta-analysis, along with the reasons for exclusion at each stage.

Figure 2. Forest plot showing the quality of life levels before and after liposuction in patients with lipedema. The standardized mean difference (SMD) and corresponding 95% confidence intervals (CI) are presented for each study. The diamond represents the overall effect size.

Figure 3. Forest plot illustrating the pain outcomes before and after liposuction in patients with lipedema. The standardized mean difference (SMD) and its 95% confidence intervals (CI) are displayed for each individual study. The diamond symbol represents the overall effect size.

Figure 4. Forest plot showing sensitivity to pressure levels before and after liposuction in patients with lipedema. The standardized mean difference (SMD) and corresponding 95% confidence intervals (CI) are presented for each study. The diamond represents the overall effect size.

Figure 5. Forest plot showing bruising levels before and after liposuction in patients with lipedema. The standardized mean difference (SMD) and corresponding 95% confidence intervals (CI) are presented for each study. The diamond represents the overall effect size.

Figure 6. Forest plot showing cosmetic impairment levels before and after liposuction in patients with lipedema. The standardized mean difference (SMD) and corresponding 95% confidence intervals (CI) are presented for each study. The diamond represents the overall effect size.

Figure 8. Forest plot showing the difficulty in walking levels before and after liposuction in patients with lipedema. The standardized mean difference (SMD) and corresponding 95% confidence intervals (CI) are presented for each study. The diamond represents the overall effect size.

Study ID	Study design	Country	Total number of patients	Age	Clinical Recommendations	Level of Evidence
Cornely et al., 2022 [19]	Retrospective cohort	Germany	504	16-78	 Immediate mobilization is a part of postoperative care for lipedema patients. Combined AMLD therapy and physical treatment are recommended for 4 weeks after the procedure. A 5-day course of antibiotics is prescribed as part of postoperative care. Thrombosis prophylaxis is administered for 3 days using low molecular- weight enoxaparin sodium. 	Π
Kruppa et al., 2022 [5]	Retrospective cohort	Germany	106	18- 68	 Early surgical intervention improves long-term outcomes in managing the disease. Favorable long-term outcomes are achievable in younger individuals with a body mass index of 35 kg/m2 or lower. The pinch test aids surgeons in assessing the surgical outcome and determining the necessary amount of lipoaspirate. 	Π
Wright et al., 2022 [21]	Case-series	USA	3	Case 1: 55, Case 2: 38, Case 3: 62		Ι
Baumgartner et al., 2020 [22]	Prospective cohort	Germany	60	22-68	 Tumescent liposuction in lipedema improves pain, edema, bruising, and movement restriction. It reduces the need for additional conservative treatments and enhances quality of life. Specialized centers with experienced surgeons should perform the procedure. 	I
Sandhofer et al., 2021	Prospective cohort	Germany	41		Study participants reported a long-lasting	II

[23]						decrease in symptom severity.	
					•	The need for conservative therapy was reduced in patients even after 12	
					•	years post-procedure. The findings suggest that liposuction is an effective	
Cablaashaaar	Due en e stirre	Commonwe	60	24 -		treatment for lipedema.	IJ
Schlosshauer et al., 2021 [24]	Prospective cohort	Germany	69	24 - 58	•	Adhering to standard guidelines for liposuction ensures the safe	II
						performance of large surgical procedures on ambulatory lipedema patients.	
van de Pas et	Prospective	Netherlands	117	40.9	•	Tumescent liposuction	II
al., 2020 [25]	cohort			- 42.2		treatment for lipoedema, whether under local or general anesthesia,	
						significantly improves health-related and disease- specific quality of life (QoL).	
					•	The general health status shows positive improvement with an	
						increased number of treatment sessions.	
Witte et al., 2020 [26]	Prospective cohort	Germany	63		•	Lymphatic insufficiency significantly influences the pathophysiology of lipoedema.	II
					•	Tumescent liposuction does not appear to reduce lymphatic function in individuals with lipoedema.	
Bauer et al., 2019 [27]	Cross- sectional	Germany	209	20- 68	•	Implementing a standardized treatment plan is essential for consistent surgical outcomes and reducing	п
					•	complications. Early intervention is crucial to prevent lipo-	
						lymphedema and irreversible damage to the lymphatic system,	
						emphasizing the importance of initiating treatment for lipedema at an early stage.	
Wollina et al., 2019	Prospective cohort	Germany	111	20- 81	•	Early intervention with liposuction is	II
[28]						recommended to reduce reliance on conservative treatment and prevent	
						irreversible sequelae of lipedema, such as	

						irreversible damage to the	
						lymphatics.	
Dadras et al., 2017 [29]	Prospective cohort	Germany	25	23- 64	•	Liposuction is an effective treatment for lipedema. However, it is crucial to complement liposuction	II
						with conservative measures.	
Baumgartner et al., 2016 [30]	Prospective cohort	Germany	85	28- 75	•	Liposuction is the most effective treatment for lipedema. However, to achieve	II
						maximum benefit, it is crucial to implement a comprehensive treatment concept.	
Rappich et al., 2015 [31]	Prospective cohort	Germany	85			Tumescent liposuction is particularly effective when applied to younger patients in the early stages of the disease, compared	Ш
					•	to older individuals with a severe form of the disease. Controlled compression therapy plays a crucial role in the overall treatment of liposuction, both before and after	
						surgical intervention.	
Wollina et al., 2014 [32]	Case-series	Germany	3	Case 1:55. Case 2:72.	•	Older patients with advanced disease require careful post-surgical monitoring.	II
				Case 3:77	•	Common adverse events in older patients with	
Rappich et al., 2011 [33]	Prospective cohort	Germany	25	22- 56	•	Water jet-assisted liposuction, when used with an appropriate operative technique, leads	II
Wollina et al., 2010 [34]	Prospective cohort	Germany	2	Case 1: 29 Case 2: 48	•	Tumescent liposuction is highly effective in enhancing the quality of life for patients with	П
				1.10	•	lipedema. However, it is important to note that lipedema is	
						not curable, and the use of conservative measures such as physiotherapy and compression is still necessary.	
					•	Expertise is required to perform tumescent liposuction procedures safely and effectively.	
Stutz et al., 2009 [35]	Prospective cohort	Germany	30	21- 63	•	Liposuction has shown a significant improvement in the quality of life for lipedema patients,	II

					•	including pain reduction, weight reduction, improvement in clothing size, and enhanced walking ability. However, prospective studies are needed to further evaluate and assess potential complications associated with liposuction in lipedema patients.	
Schmeller et al., 2006 [36]	Prospective cohort	Germany	28	22-63	•	To assess the risk of postsurgical lymphatic and other complications in women with lipedema, surgeons utilizing modified suction lipectomy techniques should provide comprehensive complication reports. Longitudinal studies are required to further investigate the incidence and long-term effects of complications associated with modified suction lipectomy in lipedema patients.	IV
Schmeller et al., 2012 [37]	Prospective cohort	Germany	112	20- 68	•	Lipedema is distinct from obesity as it is not linked to metabolic disorders like type 1 or type 2 diabetes, high blood pressure, or abnormal lipid levels. Post-surgical outcomes demonstrate a noteworthy enhancement in the quality of life for lipedema patients. Further investigation is required to determine if there is a causal relationship between hypothyroidism and lipedema, addressing the potential link between the two.	IV
Herbst et al., 2021 [38]	Retrospective cohort	USA	148	42- 62	•	An individualized approach to lipedema is recommended, and it proves to be effective even in cases involving multiple comorbidities and elderly patients. For older patients with multiple comorbidities, the use of prilocaine instead of lidocaine is	IV

	recommended to mitigate the risk of cardiotoxicity.	
--	---	--

USA: United States of America, AMLD: Active Manual Lymphatic Drainage



Study ID	Liposuction Technique								
	Fluid Instillation (Dry, wet or tumescent)	Technology used for suction (Conventional, power assisted, laser assisted, ultrasound assisted)	Any special techniques						
Cornely et al., 2022 [19]	Tumescent	PAL							
Kruppa et al., 2022 [5]	Tumescent	PAL\ WAL							
Wright et al., 2022 [21]	NM	UAL\ PAL\ WAL							
Baumgartner et al., 2020 [22]	NM	NM							
Sandhofer et al., 2021 [23]	Tumescent	PAL							
Schlosshauer et al., 2021 [24]	Tumescent	NM	Lymph-sparing liposuction						
van de Pas et al., 2020 [25]	Tumescent	NM							
Witte et al., 2020 [26]	Tumescent	WAL							
Bauer et al., 2019 [27]	Tumescent	NM							
Wollina et al., 2019 [28]	Tumescent	Conventional\ LAL	Micro-cannular liposuction\ 980 nm-diod laser assisted liposuction						
Dadras et al., 2017 [29]	Tumescent	WAL	Vibration-assisted device						
Baumgartner et al., 2016 [30]	NM	NM	NM						
Rappich et al., 2015 [31]	Tumescent	PAL\ WAL	Vibration-assisted device						
Wollina et al., 2014 [32]	Tumescent	LAL	980 nm-diode laser assisted						
Rappich et al., 2011 [33]	Tumescent	NM							
Wollina et al., 2010 [34]	Tumescent	NM							
Stutz et al., 2009 [35]	Tumescent	WAL							
Schmeller et al., 2006 [36]	Tumescent	PAL							
Schmeller et al., 2012 [37]	Tumescent	PAL							
Herbst et al., 2021 [38]	NM	NM							

NM: Not Mentioned, PAL: Power Assisted Liposuction, WAL: Water Assisted Liposuction, UAL: Ultrasound Assisted Liposuction, LAL: Laser Assisted Liposuction

Study ID	Number of treatment sessions, SD	Volume of fat removed per sessions (mL), SD	Use of compression garments	Injection technique and protocol	Follow Up Duration (Months)
Cornely et al., 2022 [19]	3 procedures at intervals of no less than 4 weeks		 Modified CDT involves accentuated manual lymphatic drainage (AMLD) with compression and physical treatment. Postoperatively, the treatment lasts for 4 weeks. Initially, four AMLD sessions are performed per week, gradually reducing to one session per week. 	 Tumescent local anesthesia (TLA) is commonly administered with analgesia or general anesthesia. Power-assisted liposuction (PAL) employs a motor-driven suction system to aid in the suction process. To facilitate proper drainage, incisions made during the procedure are intentionally left open without suturing. 	NM
Kruppa et al., 2022 [5]	3 (2-3)	6355 ± 2797	Yes	 General anesthesia was used with 24-hour postoperative monitoring. Power-assisted or water jet-assisted liposuction techniques were employed, using a tumescent solution of saline and epinephrine, up to 6000 ml per session. The surgical goal often involved megaliposuction, targeting approximately 6% of body weight in fat removal. Intraoperative "pinch test" determined the amount of lipoaspirate; post-surgery, a single dose of antibiotic prophylaxis was administered and hemoglobin and serum electrolytes were checked on the first day. 	20
Wright et al., 2022 [21]	1	Case 1: 6000 ml in one session	Yes	Case 1: Underwent Ultrasound-Assisted Liposuction (UAL) with 6 liters of aspirate	Case 1: 12, Case 2 and 3: 6

	Case 3 1st sessio (arms, calves ankles 6000 r 2nd sessio (inner and anterio thighs hips a knees 7200 r 3rd sessio (knee lower poster thighs ankles	n to s = nl) n t or , nd = nl) n s, ior and	 removed from arms and legs under general anesthesia. Case 2: Treated with Power-Assisted Liposuction (PAL) on hips and thighs under general anesthesia. Case 3: Received three Water-Assisted Liposuction (WAL) surgeries, totaling 13,050 cc of aspirate removal, with a focus on arms, calves, thighs, hips, and knees. 	
	1800 1			
Baumgartner M et al., 2020 [22]	IM NM	Yes	NM	4, 8 and 12 yrs
Sandhofer et al., 2021 [23]	5585	No	 Tumescent Fluid Injection Technique: Freshly prepared tumescent fluid heated to 37°C was used. Two people simultaneously introduced the fluid under pressure using a KMI Surgical Infusion/Irrigation Pump. Infiltration cannulas were wiped towards the upper layers until the tissue became firm, indicating tumescence. "Vivomed infiltration needles 1.2x100 mm" were used. Liposuction Technique: The PAL Liposuction System from MicroAire was utilized. Cannulas with a diameter of 3 to 4 mm were inserted through small incisions. Attention was given to the position and course of lymphatic vessels. Minimal secondary infiltration was performed if the patient 	

				experienced pain using a	
				blunt, 40 cm long	
				infiltration cannula with a	
				diameter of 2 mm.	
Schlosshauer	2.9 ± 1.9	1868.0 ±	No	NM	6 mo on
et al., 2021 [24]		885.5 per side			20 patients
[24]		Siuc			only out
					of 69
van de Pas et	NM	NM	No	Lymphoscintigraphy	
al., 2020				Technique:	
[25]				Subcutaneous injection of 99mTc in the first web	
				space, followed by	
				sequential imaging over	
				feet, knees, and inguinal	
				regions. Used mean	
				clearance percentages of radioactive protein and	
				inguinal uptake	
				percentages at 2 hours	
				post-injection as	
				functional parameters.	
				Abnormal clearance defined as <30% (with	
				<20% considered	
				abnormal and 20–30%	
				questionable), and	
				disturbed inguinal uptake	
				as <10% (with <5% abnormal and 5–10%	
				questionable).	
				 Tumescent Liposuction 	
				Protocol: Performed	
				according to standard	
				treatment by Klein, executed by an	
				experienced professional	
				specializing in lipoedema	
				treatment for over 15	
				years.	
Witte et al.,	3 (1-4)	12,922 ±	Preop: 60	Infiltration volume varied	21.5
2020 [26]		2922 over	Postop: 20	depending on the specific	
		the course		body area: 200-400 ml	
		of all		for the lower legs, 400-	
		operations		700 ml for the upper legs, and 200-300 ml for the	
				upper limbs.	
				 The infiltration process 	
				had an approximate	
D I		10100	X	duration of 10 minutes.	10
Bauer et al., 2019 [27]	3 ± 2	10100 ± 9600	Yes Preop: 163	NM	12
2013 [27]		5000	Postop: 80		
Wollina et		4,700 ±	No	Liposuction was	2.0 ± 2.1,
al., 2019		7,579 ml		performed using 2-3 mm	with
[28]				blunt cannulas connected	follow-up
				to a vacuum pump,	duration of
				generating a negative	01

Dadras et al., 2017 [29]	3	3106	Yes	 pressure of 686 mmHg. General anesthesia was not utilized during the procedure. After the liposuction, the small 5mm incisions were closed using polyamide sutures. Tumescent liposuction was performed using a solution of saline with epinephrine (1:1,000,000) following the patient's consent. 	between five and seven years for 18 patients, First post- operative follow up: 16 Second post- operative follow up: 37
Baumgartner et al., 2016 [30]	NM	NM	No	NM	48 and 96 months (4 and 8 years)
Rappich et al., 2015 [31]	2.61 ± 1	NM	Yes (postoperative for 3-7 weeks)	 Sattler's method was used to infiltrate the tumescence solution. A continuously operating roller pump system aided in the infiltration process. Aspiration was performed using a blunt 4 mm thick, vibrating microcannula with three blunt openings. 	6 months
Wollina et al., 2014 [32]	5	4000- 6000	Yes, postoperatively for 6 months	 Liposuction was performed using a 980 nm diode laser integrated into the cannula. Cannulas with diameters of 3 to 5 mm were utilized for the procedure. The cannulas were applied longitudinally, with smaller cannulas used for finer sculpting at the end. 	24-48 months (2-4 years)
Rappich et al., 2011 [33]	2.5 ± 1.1	1909 ± 874	Yes	 Vibrating cannulas with a 4 mm diameter and a handpiece attached (VibraSat®, Möller Medical, Fulda) were used. Aspiration was conducted using vibrating cannulas with 3 blunt openings at the tip arranged in a Mercedes star shape. 	6 months
Wollina et al., 2010 [34]	2	Case 1: 3600. Case 2:1800	Yes, post-surgically for 6 months	• Liposuction was carried out using blunt cannulas ranging from 2 to 5 mm in diameter.	Case 1: 6. Case 2: 48

			1			
				•	The cannulas were	
					applied longitudinally	
					during the procedure.	
				•	Smaller cannulas were	
					employed towards the	
					end of the procedure for	
					finer sculpting.	
Stutz et al	NM	1115 ±	No	•	Infiltration was	NM
Stutz et al.,			INO			11111
2009 [35]		554			performed in all cases	
					using a body-jet	
					infiltration cannula	
					(diameter = 3.5 mm) at	
					Range 2 until sufficient	
					anesthesia was achieved	
					with the infiltration	
					solution.	
				•	The aspiration procedure	
					commenced immediately	
					without waiting for fluid	
					infiltration.	
Schmeller et	NM	3017	No	•	All liposuction	12.2 (1–
	11111	3017				
al., 2006					procedures were	26)
[36]					conducted under local	months.
					tumescent anesthesia.	
				•	The administration of	
					intramuscular Demerol	
					(35 to 100 mg), Vistaril	
					(25 mg), and Versed (5	
					mg) preceded the	
					procedure.	
				•	The amount of aspirate	
					was limited to less than 5	
					L.	
					Tumescent anesthesia	
				17	included 1 L of normal	
					saline solution, 1 mL of	
					1:1000 epinephrine, 50 or	
					75 cc of 1% lidocaine,	
					and 12.5 cc of 8.4%	
					sodium bicarbonate.	
				•	The procedures utilized	
					either Xomed or Micro-	
					aire power cannulas.	
				•	Initially, accelerator and	
					mercedes-type cannulas	
					ranging from 3.0 to 4.0	
					mm were used to treat all	
					areas.	
				•	Final contouring was	
					<u> </u>	
				1	accomplished using	
					cannulas ranging from	
		0.077		-	2.0 to 2.5 mm.	
Schmeller et	NM	3077	No	•	Liposuction was	NM
al., 2012					performed on the legs,	
[37]				T	hips, and arms of each	
				1	patient.	
				•	Pure tumescent local	
				1	anesthesia (TLA) was	
				1	administered for the	
					procedure.	
L				1	procedure.	

				 Blunt vibrating microcannulas with diameters of 3 and 4 mm were used. The liposuction technique employed was power- assisted liposuction. 	
Herbst et al., 2021 [38]	2.4 ± 1.3	NM	No	NM	NM

CDT: Complex Decongestive Therapy, TLA: Tumescent Local Anesthesia, TL: Tumescent Liposuction, LAL: Laser-Assisted Liposuction, PAL: Power-Assisted Liposuction, UAL: Ultrasound-Assisted Liposuction, WAL: Water-Assisted Liposuction, AMLD: Accentuated Manual Lymphatic Drainage, SD: Standard Deviation, NM: Not Mentioned.

Item	Cornely et al., 2022 [19]	Kruppa et al., 2022 [5]	Baumgartner et al., 2020 [22]	Sandhofer et al., 2021 [23]	Schlosshauer et al., 2021 [24]	van de Pas et al., 2020 [25]	Witte et al., 2020 [26]	Bauer et al., 2019 [27]
A clearly stated aim	1	2	2	2	1	2	2	2
Inclusion of consecutive patients	2	2	0	0	2	2	2	2
Prospective collection of data	0	0	2	2	0	2	2	0
Endpoints appropriate to the aim of the study	2	2	2	2	2	2	2	2
Unbiased assessment of the study endpoint	0	0	0	0	0	0	0	0
Follow-up period appropriate to the aim of the study	2	2	2	2	2	2	2	2
Loss to follow-up less than 5%	2	2	0	0	2	2	0	2
Prospective calculation of the study size	0	0	2	2	0	2	2	0
Total Score	9	10	11	10	9	14	12	10

The items are scored 0 (not reported), 1 (reported but inadequate) or 2 (reported and adequate). The global ideal score being 16 for non-comparative studies.

Item	Wolli na et al., 2019 [28]	Dadr as et al., 2017 [29]	Baumgart ner et al., 2016 [30]	Rappi ch et al., 2015 [31]	Rappi ch et al., 2011 [33]	Wolli na et al., 2010 [34]	Stu tz et al., 200 9 [35]	Schmell er et al., 2006 [36]	Schmell er et al., 2012 [37]	Herb st et al., 2021 [38]
A clearly stated aim	2	2	2	2	2	2	2	2	2	2
Inclusion of consecuti ve patients	2	2	2	0	1	1	2	2	2	2
Prospecti ve collection of data	2	2	2	2	2	2	2	0	2	2
Endpoint s appropri ate to the aim of the study	2	2	2	2	2	2	2	1	2	2
Unbiased assessme nt of the study endpoint	0	0	0	0	0	0	0	0	0	0
Follow- up period appropri ate to the aim of the study	2	2	2	2	2	2	0	1	2	0
Loss to follow-up less than 5%	2	1	1	0	1	0	0	0	0	0
Prospecti ve calculati on of the study size	2	0	0	0	0	0	0	0	0	0
Total Score	14	11	11	8	10	9	8	6	10	8


Domain For Evaluati	ng the Meth	odologica	al Quality	y of Ca	se Rep	orts a	nd Ca	se Ser	ies	
	Selection	Ascerta	ainment	Caus	ality	Rep	orting			
	Leading E	Explanato	ory Quest	tions						
Reference	Q. 1	Q. 2	Q. 3	Q. 4	Q. 5	Q. 6	Q. 7	Q. 8	Quality Score	Risk of Bias
Wright et al., 2022	Yes	Yes	No	No	No	No	Yes	Yes	Fair Quality Study (7)	Moderate Risk
Wollina et al., 2014	Yes	Yes	Yes	No	No	No	Yes	Yes	Fair Quality Study (7)	Moderate Risk

Selection: [question 1]. Does the patient(s) represent(s) the whole experience of the investigator (center) or is the selection method unclear to the extent that other patients with similar presentations may not have been reported?

Ascertainment: [question 2]. Was the exposure adequately ascertained? [question 3]. Was the outcome adequately ascertained?


Causality: [question 4]. Were other alternative causes that may explain the observation ruled out? [question 5]. Was there a challenge/rechallenge phenomenon? [question 6]. Was there a dose-response effect? [question 7]. Was follow-up long enough for outcomes to occur?

Reporting: [question 8] Is the case(s) described with sufficient details to allow other investigators to replicate the research or to allow practitioners to make inferences related to their own practice?



	Pre-ir	nterven	tion	Post-i	nterven	tion		Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Schmeller et al., 2012	3.36	0.86	112	0.76	0.91	112	20.0%	2.93 [2.55, 3.31]	
Schlosshauer et al., 2021	6.6	1.5	96	3.7	1.4	96	23.8%	1.99 [1.64, 2.34]	
Rapprich et al., 2015	8.5	2.2	85	3.3	2.8	85	20.6%	2.06 [1.68, 2.43]	
Rapprich et al., 2011	8.7	1.7	25	3.6	2.5	25	5.3%	2.35 [1.62, 3.08]	
Dadras et al., 2017	8.38	1.06	25	4.3	1.8	25	4.7%	2.72 [1.93, 3.50]	
Baumgartner et al., 2021	3.49	0.77	60	0.69	0.81	60	8.6%	3.52 [2.94, 4.10]	
Baumgartner et al., 2016	3.35	0.84	85	0.94	1	85	17.0%	2.60 [2.19, 3.01]	
Total (95% CI)			488			488	100.0%	2.48 [2.31, 2.65]	•
Heterogeneity: $Chi^2 = 31.2$ Test for overall effect: Z =				$I^2 = 81$	%				-2 -1 0 1 2 Pre-intervention

Pre-intervention Post-intervention



	Pre-in	terven	tion	Post-i	nterven	tion	5	itd. Mean Difference	Std. Me	ean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, F	ixed, 95% Cl
Witte et al., 2020	7.14	1.19	63	1.55	1.79	63	9.0%	3.66 [3.08, 4.23]		
Schmeller et al., 2012	2.91	1.06	112	0.37	0.6	112	20.9%	2.94 [2.56, 3.32]		
Rapprich et al., 2015	6.5	3	85	2.4	2.4	85	25.8%	1.50 [1.16, 1.84]		
Dadras et al., 2017	7.38	1.79	25	3.98	1.83	25	6.7%	1.85 [1.18, 2.52]		
Baumgartner et al., 2021	2.88	1.06	60	0.88	0.91	60	15.4%	2.01 [1.57, 2.45]		
Baumgartner et al., 2016	2.88	1.01	85	0.94	0.95	85	22.2%	1.97 [1.60, 2.34]		
Total (95% CI)			430			430	100.0%	2.20 [2.03, 2.38]		•
Heterogeneity: Chi ² = 58.3	7. df = 5	(P < 0	0.00001); $ ^2 = 9$	1%				- <u>t</u>	
Test for overall effect: Z =									-4 -2 Pre-intervent	0 2 4 tion Post-intervention

	Pre-ir	nterven	tion	Post-i	nterven	tion	St	d. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Baumgartner et al., 2016	2.91	1.1	85	1.46	1.17	85	22.0%	1.27 [0.94, 1.60]	
Baumgartner et al., 2021	3.04	0.98	60	1.16	0.98	60	12.8%	1.91 [1.47, 2.34]	
Dadras et al., 2017	6.96	1.58	25	4.36	1.91	25	6.1%	1.46 [0.83, 2.09]	
Rapprich et al., 2015	8.1	2.2	85	4.3	3.1	85	21.2%	1.41 [1.07, 1.74]	
Schmeller et al., 2012	3.01	1.03	112	1.26	1.11	112	26.2%	1.63 [1.33, 1.93]	
Witte et al., 2020	7.81	1.93	63	2.45	2.62	63	11.7%	2.32 [1.86, 2.77]	
Total (95% CI)			430			430	100.0%	1.61 [1.45, 1.76]	•
Heterogeneity: $Chi^2 = 16.7$	2, df = 5	5 (P = 0)	0.005); 1	$^{2} = 70\%$					
Test for overall effect: Z =									Pre-intervention Post-intervention

	Pre-ir	nterven	tion	Post-i	nterven	tion		Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Baumgartner et al., 2016	3.32	0.89	85	1.14	1.07	85	19.5%	2.21 [1.82, 2.59]	
Baumgartner et al., 2021	3.46	0.91	60	1	0.82	60	11.0%	2.82 [2.31, 3.33]	
Dadras et al., 2017	8.98	0.81	25	5.1	1.93	25	4.9%	2.58 [1.82, 3.35]	
Rapprich et al., 2015	6.33	3.2	85	3.2	2.5	85	27.5%	1.09 [0.76, 1.41]	
Schmeller et al., 2012	3.33	0.88	112	1.08	0.91	112	23.2%	2.51 [2.15, 2.86]	· · · · · · · · · · · · · · · · · · ·
Witte et al., 2020	8.71	2.26	63	3.13	2.48	63	13.8%	2.34 [1.88, 2.79]	
Total (95% CI)			430			430	100.0%	2.07 [1.90, 2.24]	•
Heterogeneity: Chi ² = 53.5	9, df = 5	5 (P < 0)	.00001); $ ^2 = 9$	1%				
Test for overall effect: Z =									Pre-intervention Post-intervention

	Pre-in	terven	tion	Post-i	nterven	tion	S	td. Mean Difference		Std. M	ean Dif	ference	e	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI		IV, F	ixed, 9	5% CI		
Dadras et al., 2017	7.52	1.36	25	3.26	2.01	25	10.1%	2.44 [1.70, 3.19]						\rightarrow
Rapprich et al., 2015	18	3.8	25	16.8	3.5	25	18.0%	0.32 [-0.23, 0.88]			-	-		
Schmeller et al., 2012	3.06	1.02	112	1.27	0.88	112	56.6%	1.87 [1.56, 2.19]						
Witte et al., 2020	8.42	1.8	63	1.55	1.66	63	15.3%	3.94 [3.34, 4.55]						•
Total (95% CI)			225			225	100.0%	1.97 [1.73, 2.21]					٠	
Heterogeneity: $Chi^2 = 76$					96%			· · · · · · · · · · · · · · · · · · ·	-5	-1		1	3	

Test for overall effect: Z = 16.28 (P < 0.00001)

Pre-intervention Post-intervention

	Pre-ir	nterven	tion	Post-intervention			S	td. Mean Difference	Std. Mean Difference					
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI		IV, I	ixed, 95	% CI		
Rapprich et al., 2015	4.1	3.5	85	1.2	1.9	85	47.2%	1.03 [0.70, 1.35]				-		
Schmeller et al., 2012	2.03	1.36	112	0.28	0.68	112	52.8%	1.62 [1.32, 1.92]				5	-	
Total (95% CI)			197			197	100.0%	1.34 [1.12, 1.56]					•	
Heterogeneity: $Chi^2 = 7$.					6			(7	-2	-1	0	1	2	
Test for overall effect: Z	= 11.95	(P < 0	.00001))					P	re-interver	tion Post	-interver	ntion	

